Diagnostic Impact
Despite the significant EGM burden reduction achieved by this key EGM selection tool, the number of days with a TP EGM available for review did not drop significantly: 0.8%, 2.1%, 0.2%, and 0.0%, respectively. As a consequence, 99.2% of patients diagnosed with an arrhythmia were diagnosed on the same day as they would have been if all EGMs were reviewed. Of the remaining patients with more than one TP day, but their first TP day was missed by key EGM selection, no diagnostic delay for AF, 9.5 day delay for tachycardia, 6.0 day delay for bradycardia, and no diagnostic delay for pause was observed. Note that these diagnostic delays assume a daily EGM review, with a diagnosis occurring on the first day a TP EGM is available. Therefore, such delays may not be observed if transmitted EGMs were reviewed monthly. The rarity and negligible magnitude of diagnostic delays was also supported by Kaplan-Meier analysis, which demonstrated nearly identical freedom from diagnosis trends in the first-year post-implant when reviewing all vs. key EGMs.